| Literature DB >> 33172379 |
Naina M P Maideen1, Rajkapoor Balasubramanian2, Sambathkumar Ramanathan2.
Abstract
Hypertension is one of the leading risk factors for stroke, myocardial infarction and untimely death. The prevalence of hypertension is extremely high among the global population, and many of them depend on modern medicines to manage their blood pressure. The modern antihypertensive medications include angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), calcium channel blockers (CCBs), diuretics, beta-adrenergic blockers, direct renin inhibitors, direct-acting vasodilators, alpha-adrenergic blockers and centrally acting drugs that are associated with many harmful and undesirable effects. The patients may consider traditional herbal medicines as a good strategy to manage chronic conditions due to the reasons such as perceived failure of allopathic medicines, relatively high cost of allopathic medicines, social-cultural practices and/or herbal knowledge, poor access to medical facilities and safety concerns about modern medicines. Nigella sativa (Black seeds) has been used to treat various conditions, including hypertension, obesity, diabetes, cancer, etc. Hence, the antihypertensive potential of N. sativa is analyzed in this review. The literature was searched in databases including Medline/PMC/PubMed, Google Scholar, ScienceDirect, Directory of Open Access Journals (DOAJ) and reference lists to identify articles associated with antihypertensive properties of N.sativa. Numerous randomized controlled trials and animal studies reported that N.sativa has potential antihypertensive effects. Hence, N. sativa could be used effectively to manage patients with stage 1 hypertension, and the patients using modern antihypertensive medications could reduce their doses by adding N. sativa into their regimen as adjuvant therapy. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Entities:
Keywords: Nigella sativa; black seeds; hypertension; kalonji; nigellone.; thymol; thymoquinone
Mesh:
Substances:
Year: 2021 PMID: 33172379 PMCID: PMC8762160 DOI: 10.2174/1573403X16666201110125906
Source DB: PubMed Journal: Curr Cardiol Rev ISSN: 1573-403X
Clinical studies supporting the use of N. sativa to manage hypertension.
|
|
|
|
|---|---|---|
| 1 | Randomized, double-blind, placebo-controlled clinical trial [ | Significant reduction of SBP, DBP, and LDL-cholesterol. |
| 2 | Randomized, double-blind, placebo-controlled clinical trial [ | Improvement in BP, FBG, serum lipids, BMI, waist-hip ratio, ALT and creatinine. |
| 3 | Randomized, double-blind, placebo-controlled clinical trial [ | Significant decline in SBP, body weight, and waist circumference. |
| 4 | Clinical study [ | Improvement in BP, FBG, waist circumference, LDL, HDL and triglycerides. |
| 5 | Open labeled study [ | Significant improvement in SBP, DBP, LDL. |
| 6 | Randomized, double-blind, placebo-controlled clinical trial [ | Significant decrease in SBP, and DBP. |
| 7 | Randomized, double-blind, placebo-controlled clinical trial [ | Significant lowering of SBP and significant increase in HDL. |
| 8 | Single-blind, nonrandomized controlled clinical trial [ | Significant reduction of SBP. DBP, MAP, TC, LDL, TC/HDL, LDL/HDL and significant elevation of HDL. |
| 9 | Randomized, double-blind, controlled clinical trial [ | Slight decrease in SBP and DBP. |
Proposed mechanisms of Antihypertensive activity of N. sativa.
|
|
|
|
|
|---|---|---|---|
| 1 | Calcium channel blockade | Magyar J | Thymol of |
| 2 | Calcium channel blockade | Salem ML [ | Nigellone of |
| 3 | Calcium channel blockade | Cherkaoui-Tangi K | Treatment of isolated rat aorta with |
| 4 | Calcium channel blockade | Jaarin K | Reduction of blood pressure |
| 5 | Calcium channel blockade | Alam MA | Simultaneous administration of |
| 6 | Diuretic activity | Zaoui A | Increased urinary excretion of electrolytes, such as Na+, K+, Cl- and urea. |
| 7 | Diuretic activity | Zeggwagh NA | Accelerated urinary excretion of electrolytes and glomerular filtration rate (GFR). |
| 8 | Angiotensin-converting enzyme (ACE) inhibition | Jaarin K | Inhibition of angiotensin-converting enzyme (ACE) and reduction of blood pressure, in L-NAME- induced hypertensive rats. |
| 9 | Angiotensin-converting enzyme (ACE) inhibition | Enayatfard L | Antagonized effect of elevation of SBP and MAP in angiotensin II-induced hypertensive rats. |
| 10 | Angiotensin-converting enzyme (ACE) inhibition | Ahad A | Concurrent administration of |
| 11 | Reduction of oxidative stress | Khattab M | Inhibition of the production of superoxide radical, in nitric oxide (NO) deficient hypertensive rats. |
| 12 | Reduction of oxidative stress | Sayed HM | Antioxidant effects in L-NAME-induced hypertensive rats. |
| 13 | Increased cardiac heme oxygenase-1 (HO-1) activity | Jaarin K | Increased cardiac heme oxygenase-1 (HO-1) activity leads to a reduction of angiotensin II-induced inflammation and NADPH oxidase-mediated oxidative stress resulting in attenuation of blood pressure in L-NAME induced hypertensive rats. |
| 14 | Prevention of loss of plasma nitric oxide (NO) | Jaarin K | |
| 15 | Cardiac depressant activity | El Tahir KE | Decreased blood pressure probably through the reduction of heart rate and myocardial contractility |